Magnetar Financial LLC Exelixis, Inc. Transaction History

Magnetar Financial LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $1,615 - $1,878	108 Added 0.26%	41,270 $662,000
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $645,420 - $916,677	41,162 New	41,162 $645,000
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $438,307 - $591,083	-23,834 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$20.67 - $26.94 $492,648 - $642,087	23,834 New	23,834 $583,000
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $246,499 - $371,624	-17,047 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$15.15 - $18.89 $214,599 - $267,576	-14,165 Reduced 45.38%	17,047 $300,000
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $691,345 - $995,350	31,212 New	31,212 $691,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Magnetar Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Magnetar Financial LLC with notifications on news.